64 results about "Active immunity" patented technology

A number of immunologically active agents are described, including an isolated protein or polypeptide that includes the amino acid sequence of SEQ ID NO: 1, immunogenic conjugates containing either the protein or polypeptide, a full-length Pneumocystis kexin, or a full length Streptococcus pneumoniae pneumococcal surface protein A (PspA), antibodies recognizing the protein or polypeptide or the immunogenic conjugates (particularly the epitope of SEQ ID NO: 1), and nucleic acid molecules that encode the protein or polypeptide, as well as DNA constructs, expression vectors, and host cells that contain the nucleic acid molecules. Disclosed uses of the antibodies, immunogenic conjugates, and DNA constructs include inducing passive or active immunity to treat or prevent pathogen infections, particularly by a Pneumocystis organism, in a patient.

The invention discloses a broad-spectrum anti-tumor double-plasmid reproducible DNA vaccine. Active ingredients of the broad-spectrum anti-tumor double-plasmid reproducible DNA vaccine comprise a tumor antigen compound gene-carrying anti-tumor antigen replicon DNA vaccine pSVK-CACA and a tumor blood vessel compound gene-carrying anti-tumor blood vessel replicon DNA vaccine pSVK-CAVE, wherein the tumor antigen compound gene-carrying anti-tumor antigen replicon DNA vaccine pSVK-CACA and the tumor blood vessel compound gene-carrying anti-tumor blood vessel replicon DNA vaccine pSVK-CAVE are constructed by using a replicon DNA vaccine carrier pSVK as a starting carrier. The broad-spectrum anti-tumor double-plasmid reproducible DNA vaccine provides a new choice for anti-tumor active immunity treatment and has a broad application prospect.

The invention provides an active immune attack identification method. The active immune attack identification method comprises the following steps: acquiring a real-time data stream of a charging device; carrying out real-time detection and classification on the data flow through a stack type self-encoding network model so as to judge whether abnormal data exists in the data flow or not, and directly forwarding the data when the abnormal data does not exist; and when abnormal data exists, intercepting the real-time data flow, sending out an alarm prompt, generating a log record, and meanwhile,stopping the machine. The invention further provides a charging device. Compared with the prior art, the data obtained by the charging device is analyzed and classified through the stack type auto-encoder network model, and the probability of being attacked by the network is output, so that whether the data is attacked or not is judged, corresponding operation is executed, the information safetyand the operation reliability of the charging device are guaranteed, and the safety of a power grid is guaranteed.

The present invention provides a method for producing a vaccine against cancerous disease, and the vaccine itself. This method involves first using one or more antibodies that are specifically effective against one or more antigens specially expressed by the tumor cells to select one or more mimotopes of said antigens from a phage peptide library. To obtain the vaccine, said mimotopes are conjugated to a macromolecular carrier singly or multiply in the form of their mono-, di-, tri- or oligomers. When administered, the inventively produced vaccine leads to a humoral immune response and thus to the formation of an active immunity as a consequence of vaccination.

The present invention discloses a simulation epitope of 12 amino acids of human cell B specificity expression membrane molecule CD 20 and its polypeptide epitope vaccine constructed by using said simulation spitope. Said invention also provides a method for screening simulation epitope of CD 20 molecule by using Rituximab as ligand, and provides its amino acid sequence, Gln-Asp-Lys-Leu-Th-Gln-Try-Pro-Lys-Try-Leu-Glu. Said invention also provides a method for chemically-synthesizing simulation epitope of 12 amino acids and making it be chemically-coupled with keyhole limpet hemo cyanin (KLH) to obtain the successfully-constructed vaccine. Besides, said invention also provides the concrete application of said vaccine.

The invention provides a preparation method of a tumor fusion cell vaccine. The preparation method comprises the following steps of fusing genes of an alpha-TCR (T cell receptor) and a beta-TCR into an alpha and beta-TCR; obtaining a recombinant plasmid; constructing the alpha and beta-TCR into a shuttle plasmid pMP71-alpha and beta-TCR; transfecting gamma-delta T cell by the gene of alpha and beta-TCR; using an electric fusion technique to fuse the gamma-delta T cell and tumor cell into a vaccine. The preparation method has the advantages that the fusion cell is formed by the gamma-delta T cell transfected by the gene of alpha and beta-TCR and the tumor cell, so as to prepare the vaccine; the specificity of tumor cell can be identified, the capability of the fusion cell inducing the withering of the tumor cell is strongest, and the active immunity of the body receptor is stimulated to treat tumors.

The invention provides a trusted cloud platform measurement system and method. The system comprises at least one virtual trusted root front end driving module for acquiring an application request andsending the application request to a virtual trusted root back end driving module, wherein the virtual trusted root back end driving module is used for adding a label corresponding to each virtual machine, and generating an identification application request and sending to a physical trusted root driving module; a life cycle management module for generating a measurement instruction according to astarting behavior of each virtual machine and system environment of a host machine, and sending the measurement instruction to the physical trusted root driving module to execute through the virtualtrusted root management module; the physical trusted root driving module for performing trusted measurement test on the label application request to generate a measurement result, and sending the result to the physical trusted root module so that the physical trusted root module determines whether the host machine executes the application request according to the measurement result. By implementing the measurement system disclosed by the embodiment, the security of the cloud platform body is reinforced, the active immunity mechanism on malicious attack by the cloud platform is realized, and the solid foundation is laid for constructing the safe and trusted electric cloud platform.

The invention relates to preparation method of prostatic cancer specific DC cell vaccine which is insensitive to TGF-belta, which can treat prostatic cancer effectively, and is prostatic cancer specific immunization gene treatment with genuine with truly implemented combination of active immunity and adoptive cellular immunity. The technical scheme of the present invention applied is: 1) constructing retrovirus containing dominant negative TGF-belta II type (T belta RIIDN) plasmid; 2) separating, culturing and identifying DC cells loaded with prostatic cancer antigen; 3) transfection of DC cells to obtain T belta RIIDN-DC cells; 4) vitro experiments of the T belta RIIDN-DC cells; 5) antitumor estimate of the DC vaccine in vivo; 6) CTL activity detection in vivo.

Methods of treating eosinophilia by down regulating eotaxin and at least one other Th-2 related cytokine are dislosed as are multivalent immunogenic compositions that generate an active immune response in a subjet comprising autoantibodies to eotaxin-1, eotaxin-2, IL-4, IL-5, IL-9, and IL-13 and treatment methods using such compositions.

The invention belongs to the technical field of medicine, and relates to a method for constructing a ligand-mediated nano-preparation targeting dendritic cells as a tumor vaccine carrier. In the present invention, tumor antigen peptides or complexes formed by tumor antigen peptides and heat shock proteins are encapsulated in ligand-modified nano-preparations, and the ligands are antibodies that can specifically bind to dendritic cell surface receptors, thereby Specifically target dendritic cells, and present antigen information to the cell surface through the uptake, processing and processing of nano-preparations by dendritic cells, and then realize the recognition of tumor antigen information by specific cytotoxic T lymphocytes, Make the body produce active immunity, eliminate tumor cells, and achieve the therapeutic effect on tumors. The preparation method of the nano-preparation tumor vaccine provided by the invention is reasonable in design, simple in preparation and has broad application prospects.

The invention belongs to the field of animal feeds, and particularly discloses a feed additive capable of enhancing the immunity of rabbits and a preparation method of the feed additive. According to the feed additive capable of enhancing the immunity of the rabbits and the preparation method of the feed additive disclosed by the invention, the feed additive is prepared from the following active components of radix cynanchi atrati, mint, poria cocos, golden buckwheat rhizomes, rice beans, pittosporum illicioides, common sowthistle herbs, aralia elata, dioscorea subcalva prain et burhll, shiitake mushrooms, luffa vegetable sponges, fortune eupatorium herbs, atractylodes lancea, eucalyptus citriodora leaves, white mulberry root bark, millettia specisoa roots, garlic powder and ficus simplicissima in certain parts by weight. The preparation method of the feed additive capable of enhancing the immunity of the rabbits disclosed by the invention is simple, all the raw materials have complementary advantages, and the mutual synergistic or resistant effects of the raw materials are utilized, so that the appetite of the rabbits is fundamentally stimulated, the constitutions of the rabbits are strengthened, and the disease resistance of the rabbits is improved; the use of antibiotics is reduced, so that the quality of rabbit meat is improved, besides, various special bioactive substances can be provided, the establishment of an active immunity system of the rabbits is stimulated, and the disease prevention and disease resistance of the rabbits are strengthened, so that the appetite of the rabbits is good, the excrement of the rabbits is moist, the skin of the rabbits is red, the hair of the rabbits is bright, and the economic utilization value is increased.

Chimeric double peptide vaccines are disclosed, useful for inducing active immunity against Candida fungal infections. The chimeric peptide comprises an Fba peptide and an Met6 peptide, covalently linked to one another, with or without an intermediate linker. Fba and Met6 are cell surface components of Candida. When used as a vaccine, the chimeric double peptide vaccine induces stronger protective immunity against fungal infection than does the Fba peptide alone, or the Met6 peptide alone, or a mixture (not covalently linked) of the two peptides.

The invention relates to the field of molecular biology and immunology. Specifically, active immunity intervention is performed on a mouse with virus-like particles presenting IL-33 (interleukin-33) whole protein to induce the organism to produce specific IgG antibody response resistant to IL-33, so that the expression level of IL-33 in the mouse is decreased continuously, the anti-tumor immunity response of the organism is enhanced, and tumor growth is inhibited.